Please login to the form below

Ranbaxy

This page shows the latest Ranbaxy news and features for those working in and with pharma, biotech and healthcare.

Nearly half of all clinical trials not published

Drilling down into the data provides a mixed picture for the pharma industry - at one end of the scale is Ranbaxy, which has published no results for any of the 35

Latest news

Lundbeck challenge to EC pay-for-delay ruling fails

The four generics companies - Generics UK, Arrow, Alpharma and Ranbaxy - were fined around 52m, and those judgments have also been upheld by the General Court of the EU.
India denies Vertex patent on cystic fibrosis drug Orkambi

The patent was opposed by the Indian Pharmaceutical Alliance (IPA), a trade organisation representing India's larger pharmaceutical companies, including Cipla, Dr Reddy's Labs, Lupin, Nicholas Piramal, Ranbaxy and Wockhardt.
Heart drug sales continue downward spiral

The Swiss firm has managed to delay some generic forms of its drug onto the market until last year, when Ranbaxy was granted approval to sell its copycat form of valsartan.
Takeda to pay $2.4bn to settle Actos cancer suits

Actos has generated more than $16bn in sales since its 1999 release, according to court filings, but now also faces generic competition from India's Ranbaxy Laboratories.
Teva slapped with $512m fine on pay-for-delay deal

Ranbaxy Laboratories. ... Mylan and Ranbaxy, which are also defendants in the case, are not part of the settlement.

More from news
Approximately 6 fully matching, plus 92 partially matching documents found.

Latest Intelligence

Pharma deals in April 2015

The acquisition of this portfolio with sales of INR 150 Crores, will help Dr Reddy's maintain a competitive edge with fellow Indian rival Sun Pharmaceuticals, following its acquisition of Ranbaxy
Allergan and taking a specialised approach

But for the likes of GSK, Novartis and Lilly with their asset swap agreement, Forest Laboratories and its acquisition of Actavis, and the various dealings at Merck &Co, BMS, Ranbaxy and
Pharma deals during April 2014

for its stake in Ranbaxy in 2008, not to mention the 2013 $500m payment to the US authorities to settle 7 felony charges. ... is rumoured that a solution will be to replace the Ranbaxy brand with the Sun Pharma moniker at least in the US.
Deal Watch table for April 2014

Ranbaxy Laboratories/ Sun Pharmaceuticals. Acquisition. Generics including Lipitor, Nexium, Diovan. 3, 200.
Positive prospects for pharma in Latin America

Since 2008, more foreign companies such as Takeda, Daiichi Ranbaxy and others have been allowed to set operations in the country, increasing competition and consolidation.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

Competition from within

Teva (Israel), CSL (Australia) and Aspen (South Africa) are notable exceptions, with the Indian generic giants Sun and Ranbaxy - which have since merged - the only representation from the ‘BRIC’ markets (Brazil,
Exploring MINT: Part 3 - Nigeria

as Indian Cipla, Hetero and Ranbaxy among those supplying low-cost generic ARVs to African governments.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....